Pharmacology of benzamidine-type thrombin inhibitors.
Findings on the pharmacology of derivatives of benzamidine characterized as potent competitive inhibitors of the clotting enzyme thrombin were presented including data on their toxicity. Bis-benzamidines and amidinophenylalanine amides were shown to exert pharmacodynamic effects in intact animals and isolated preparations (hypotension; influence on smooth muscle reactions to serotonin and histamine). Studies with 14C-4-amidinophenylpyruvic acid and 3H-N alpha-tosyl-(3-amidino)-phenylalanine piperidide on the pharmacokinetics in rabbits showed that benzamidine derivatives are suited, in principle, for use as anticoagulants in vivo. Pharmacokinetic properties of individual thrombin inhibitors have to be taken into account in order to reach and maintain adequate plasma levels. The antithrombotic effect of benzamidine-type thrombin inhibitors in animals experiments is directly related to their antithrombin activity.
D000578:Amidines / Q000494:pharmacology*; D000818:Animals; D000925:Anticoagulants; D001550:Benzamidines / Q000494:pharmacology* / Q000633:toxicity; D007022:Hypotension / Q000139:chemically induced; D007928:Lethal Dose 50; D051379:Mice; D010667:Phenylpyruvic Acids / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013917:Thrombin / Q000037:antagonists & inhibitors*
D000578:Amidines; D000925:Anticoagulants; D001550:Benzamidines; D010667:Phenylpyruvic Acids; C006492:amidinophenylpyruvic acid; D013917:Thrombin